Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by Jacob Oren Levitt
Based on 6 articles published since 2010
(Why 6 articles?)
||||

Between 2010 and 2020, Jacob Levitt wrote the following 6 articles about Psoriasis.
 
+ Citations + Abstracts
1 Review A review of toxicity from topical salicylic acid preparations. 2014

Madan, Raman K / Levitt, Jacob. ·Beth Israel Medical Center, Mount Sinai Health System, New York, New York; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. · Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jacob.levitt@mssm.edu. ·J Am Acad Dermatol · Pubmed #24472429.

ABSTRACT: Topical salicylic acid is often used in dermatologic conditions because of its keratolytic, bacteriostatic, fungicidal, and photoprotective properties. The bioavailability of salicylic acid differs depending on the vehicle used and pH of transcellular fluids. Although rare, salicylic acid toxicity (salicylism) can occur from topical application. Physicians should be mindful of the potential for salicylism or even death from topically applied salicylic acid.

2 Article Advanced Therapy Treatment for Psoriasis: A Single-Site Retrospective Study of Prescribing Outcomes. 2017

Kim, Carey / Joerg, Lucie / Levitt, Jacob. ·Department of Medicine, Mount Sinai Beth Israel, New York, NY; Carey_Kim@nymc.edu. · Department of Dermatology, The Mount Sinai Hospital, New York, NY. ·Skinmed · Pubmed #29282198.

ABSTRACT: -- No abstract --

3 Article Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. 2014

Luber, Adam J / Tsui, Cindy L / Heinecke, Gillian M / Lebwohl, Mark G / Levitt, Jacob O. ·Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. · Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Jacob.levittmd@gmail.com. ·J Am Acad Dermatol · Pubmed #24388425.

ABSTRACT: BACKGROUND: Infliximab often requires dose escalation to maintain response. Studies regarding long-term durability and dose escalation patterns for psoriasis are few. OBJECTIVE: We sought to evaluate dose escalation patterns in psoriatic patients to identify factors of lack of optimal response to infliximab. METHODS: A retrospective cohort study included 93 patients (216.3 patient-years) treated with infliximab for psoriasis. Kaplan-Meier analysis assessed drug durability. RESULTS: A median infliximab dose of 5.42 mg/kg/mo (range: 2.71-10.83) for a mean of 28 months was administered. Two thirds of patients received a dose escalation. Concurrent methotrexate extended duration of therapy (by a mean ± SD of 19.5 ± 8.1 months, P = .034), including time until first dose escalation (by a mean ± SD of 12.0 ± 6.1 months, P = .037), and failure (by a mean ± SD of 20.7 ± 6.7 months, P = .034). Patients who increased the infusion frequency before increasing the dose remained on infliximab 8.4 months longer than those who first increased the dose (P = .045). Four patients experienced adverse events; 2 required discontinuation. LIMITATIONS: Psoriasis Area and Severity Index, infliximab levels, and antibody titers were not measured. CONCLUSIONS: Dose escalation optimizes durability of infliximab. The probability of maintaining response is enhanced by concomitant methotrexate and increasing the infusion frequency before increasing the dose.

4 Article Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. 2013

Heinecke, Gillian M / Luber, Adam J / Levitt, Jacob O / Lebwohl, Mark G. · ·J Drugs Dermatol · Pubmed #24085044.

ABSTRACT: BACKGROUND: Patients with moderate to severe psoriasis may not respond adequately to single systemic agent and may require combination systemic therapy. OBJECTIVE: To evaluate the prevalence, indications, and response to combination systemic therapy with ustekinumab for psoriasis in a tertiary referral center. METHODS: This retrospective study comprised 102 psoriasis patients treated with ustekinumab at a single tertiary care center. Data was collected pertaining to history of psoriasis, past and current therapies including use of concomitant psoriasis agents, response to therapy, and side effects while on ustekinumab. RESULTS: Twenty-two of 102 (22%) patients were identified as receiving combination systemic treatment involving ustekinumab and at least one additional agent. The most common indication for combination therapy was psoriatic arthritis (35%), followed by bridging therapy (26%), inadequate psoriasis control (13%), prevention of non-melanoma skin cancers (17%), and control of palmoplantar disease (9%). Methotrexate was the additional agent in 12 patients, cyclosporine in 7 patients, acitretin in 5 patients, and 1 patient received a second biologic agent, first etanercept and then adalimumab. Overall, the reduction in body surface area (BSA) was 80% for patients on combination therapy. For those patients on combination therapy for psoriatic arthritis, 75% had resolution or stabilization of their symptoms. Only one patient, receiving cyclosporine, discontinued combination therapy due to adverse side effects. CONCLUSION: Combination systemic therapy with ustekinumab can be effective and well tolerated for patients who cannot be adequately treated with ustekinumab alone.

5 Minor Reply to 'complementary data for long-term infliximab use in psoriasis'. 2014

Luber, Adam J / Tsui, Cindy L / Heinecke, Gillian M / Lebwohl, Mark G / Levitt, Jacob O. ·Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. · Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Jacob.levittmd@gmail.com. ·J Am Acad Dermatol · Pubmed #25128112.

ABSTRACT: -- No abstract --

6 Minor Ophthalmic cyclosporine for the treatment of psoriatic conjunctivitis. 2014

Habeshian, Kaiane A / Levitt, Jacob Oren. ·Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. · Department of Dermatology, Mount Sinai Hospital, New York, New York. Electronic address: jacoblevittmd@gmail.com. ·J Am Acad Dermatol · Pubmed #25037807.

ABSTRACT: -- No abstract --